RxDoctor Payments Data

Scott Silvia, MD

Family Medicine · El Paso, TXNPI 1558453670

Payments from drug & device makers

$338in general payments, 2019–2025

Across 13 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$110
  • GSK$104
  • Sanofi Pasteur Inc.$77
  • Abbott$25
  • Novo Nordisk$23

What the payments were for

  • Food & beverage$26177%
  • Gifts$7723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$110
GSK7$104
Sanofi Pasteur Inc.3$77
Abbott1$25
Novo Nordisk1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$338 in reported general payments places this provider in the 40th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$147,548
Medicare patients
323
Services billed
3,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide39$54,654
ShingrixVaricella-Zoster Ge/As01b/Pf191$42,239
OzempicSemaglutide28$39,111
RybelsusSemaglutide17$36,151
JanuviaSitagliptin Phosphate31$31,923
ProliaDenosumab18$31,273
ArexvyRsvpref3 Antigen/As01e/Pf68$21,234
FarxigaDapagliflozin Propanediol16$20,376
EliquisApixaban14$11,465
Colesevelam Hcl25$10,899
Boostrix TdapDiphth,pertuss(Acell),tet Vac138$9,601
PremarinEstrogens, Conjugated12$4,567
Alosetron Hcl13$4,236
Levothyroxine Sodium401$4,215
SynthroidLevothyroxine Sodium58$3,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$23$75,26245 claims
GSKShingrix, Arexvy, Havrix$104$64,804272 claims
AmgenProlia$110$31,27318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →